Substance use disorders remain a major global health challenge
The newly proposed KDIGO recommendation advocates the initiation of SGLT2 inhibitors for all CKD patients with an eGFR greater than 20 ml/min without any contraindications
Although the FDA has reported that several different dosages of semaglutide (aka Ozempic and Wegovy) are still in limited supply, Novo Nordisk CEO Lars Jrgensen told Forbes that his company has ramped up manufacturing. The company is now putting more starter doses the first patients receive until their doctors find the best dose level for them into the supply chain than it had initially projected for 2024
This is especially important for athletes who are exposed to high loads and risk injury
Understanding kidney-related concerns with GLP-1 agonists provides additional context for this consideration
This advanced therapy bypasses digestive limitations to restore optimal NAD+ levels, enhancing mitochondrial function, supporting DNA repair, and activating longevity pathways within your cells for comprehensive improvements in mental clarity, physical vitality, and overall wellbeing
